A Cost-Effectiveness Analysis for Post-ERCP Pancreatitis Prophylaxis in the United States

Post-ERCP Pancreatitis (PEP) is the most common adverse event following ERCP; responsible for substantial morbidity and healthcare expenditures of at least $200 million. Therapies for PEP prevention include pancreatic stent placement (PSP), rectal indomethacin, sublingual nitrates, and aggressive Lactated Ringer ’s (LR) hydration. Our objective was to determine which PEP prophylactic strategies are cost-effective.

Source: Clinical Gastroenterology and Hepatology - September 2, 2021 Category: Gastroenterology Authors: Nikhil R. Thiruvengadam, Monica Saumoy, Yecheskel Schneider, Sara Attala, Joseph Triggs, Peter Lee, Michael L. Kochman Source Type: research